Lessons learned from gene expression profiling of cutaneous T-cell lymphoma

British Journal of Dermatology

Volumn 169, Issue 6, 2013, Pages 1188-1197

  Dulmage, B O ^a   Geskin, L J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD52 ANTIGEN; CD70 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; EPHRIN RECEPTOR A4; FAS LIGAND; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NEURONAL APOPTOSIS INHIBITORY PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PROTEIN BCL 11A; PROTEIN BCL 2; PROTEIN KINASE LCK; PROTEIN PLS3; PROTEIN TOX; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE C; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 1; STAT3 PROTEIN; STAT4 PROTEIN; STAT5B PROTEIN; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VERSICAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR PROTEIN;

CD4+ T LYMPHOCYTE; CELL DEATH; CUTANEOUS T CELL LYMPHOMA; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MICROARRAY ANALYSIS; MYCOSIS FUNGOIDES; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEZARY CELL; SEZARY SYNDROME; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH2 CELL; CELL DIFFERENTIATION; CELLULAR IMMUNITY; GENETICS; IMMUNOLOGY; METABOLISM; SKIN TUMOR; TUMOR GENE;

CELL DEATH; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; GENES, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; IMMUNITY, CELLULAR; LYMPHOMA, T-CELL, CUTANEOUS; NEOPLASM PROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, UNTRANSLATED; SKIN NEOPLASMS; TH2 CELLS;

EID: 84889050276     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12578     Document Type: Review

References (90)

1. Willemze R, Jaffe ES, Burg G, et al,. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-88.
2. Kim YH, Liu HL, Mraz-Gernhard S, et al,. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-66.
3. Foss FM,. An oncologist's approach to therapy for cutaneous T-cell lymphoma. Clin Lymphoma 2000; 1 (Suppl. 1): S9-14.
4. Foss FM, Sausville EA,. Prognosis and staging of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1011-19.
5. van Doorn R, van Kester MS, Dijkman R, et al,. Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome. Blood 2009; 113: 127-36.
6. Booken N, Gratchev A, Utikal J, et al,. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008; 22: 393-9.
7. Lee CS, Ungewickell A, Bhaduri A, et al,. Transcriptome sequencing in Sézary syndrome identifies Sézary cell and mycosis fungoides-associated LncRNAs and novel transcripts. Blood 2012; 120: 3288-97.
8. Mirvish ED, Pomerantz RG, Geskin LJ,. Lack of novel Merkel cell polyomavirus in mycosis fungoides tumors. J Invest Dermatol 2010; 130: S29.
9. Kari L, Loboda A, Nebozhyn M, et al,. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477-88.
10. Mao X, Orchard G, Mitchell TJ, et al,. A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol 2008; 35: 899-910.
11. Hahtola S, Tuomela S, Elo L, et al,. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res 2006; 12: 4812-21.
12. Tracey L, Villeundas R, Dotor AM, et al,. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003; 102: 1042-50.
13. Shin J, Monti S, Aires DJ, et al,. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007; 110: 3015-27.
14. Goswami M, Duvic M, Dougherty A, Ni X,. Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome. J Cutan Pathol 2012; 39: 500-7.
15. Zhang Y, Wang Y, Yu R, et al,. Molecular markers of early-stage mycosis fungoides. J Invest Dermatol 2012; 132: 1698-706.
16. Wang Y, Su M, Zhou LL, et al,. Deficiency of SATB1 expression in Sézary cells causes apoptosis resistance by regulating FasL/CD95L. Blood 2010; 117: 3826-35.
17. van Doorn R, Dijkman R, Vermerr MH, et al,. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis. Cancer Res 2004; 64: 5578-86.
18. Mao X, Orchard G, Lillington DM, et al,. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004; 151: 546-56.
19. Gery I, Gershon RK, Waksman BH,. Potentiation of the T-lymphocyte response to mitogens. J Exp Med 1972; 136: 128-42.
20. Jones CL, Ferreira S, McKenzie RC, et al,. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma. J Invest Dermatol 2012; 132: 2042-9.
21. Nebozhyn M, Loboda A, Kari L, et al,. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006; 107: 3189-96.
22. Geskin LJ, Akilov OE, Linzer DE, et al,. Age-matched multiplex analysis reveals global immune dysregulation in patients with CTCL. J Invest Dermatol 2011; 131 (Suppl. 1): S92.
23. Pomerantz RG, Mirvish ED, Erdos G, et al,. Novel approach to gene expression profiling in Sézary syndrome. Br J Dermatol 2010; 163: 1090-4.
24. van Kester MS, Borg MK, Zoutman WH, et al,. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 2012; 132: 2050-9.
25. Wu J, Nihal M, Siddiqui J, et al,. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129: 1165-73.
26. Zoi-Toli O, Vermeer MH, De Vries E, et al,. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000; 143: 313-19.
27. el-Khatib M, Stanger BZ, Dogan H, et al,. The molecular mechanism of FasL-mediated cytotoxicity by CD4+ Th1 clones. Cell Immunol 1995; 163: 237-44.
28. Klemke CD, Brenner D, Weiss EM, et al,. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous lymphoma cells from activation-induced cell death. Cancer Res 2009; 69: 4175-83.
29. Lotem J, Sachs L,. Different mechanisms for suppression of apoptosis by cytokines and calcium mobilizing compounds. Proc Natl Acad Sci U S A 1998; 95: 4601-6.
30. Ni X, Hazarika P, Zhang C, et al,. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682-92.
31. Sors A, Jean-Louis F, Pellet C, et al,. Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006; 107: 2354-63.
32. Hartenstein B, Teurich S, Hess J, et al,. Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J 2002; 21: 6321-9.
33. Vowels BR, Lessin SR, Cassin M, et al,. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-73.
34. Murphy KM, Ouyang W, Szabo SJ, et al,. T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr Top Microbiol Immunol 1999; 238: 13-26.
35. Nishikomori R, Usui T, Wu CY, et al,. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol 2002; 169: 4388-98.
36. Bueno OF, Brandt EB, Rothenberg ME, Molkentin JD,. Defective T cell development and function in calcineurin A beta-deficient mice. Proc Natl Acad Sci U S A 2002; 99: 9398-403.
37. Bégué E, Jean-Louis F, Bagot M, et al,. Inducible expression and pathophysiologic function of T-plastin in cutaneous T-cell lymphoma. Blood 2012; 120: 143-54.
38. Hafner C, Schmitz G, Meyer S, et al,. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004; 50: 490-9.
39. Hirose J, Kawashima H, Yoshie O, et al,. Versican interacts with chemokines and modulates cellular responses. J Biol Chem 2001; 276: 5228-34.
40. Holen HL, Nustand K, Aashein HC,. Activation of EphA receptors on CD4+CD45RO+ memory cells stimulates migration. J Leukoc Biol 2010; 87: 1059-68.
41. Lin CS, Lau A, Huynh T, Lue TF,. Differential regulation of human T-plastin gene in leukocytes and non-leukocytes: identification of the promoter, enhancer, and CpG island. DNA Cell Biol 1999; 18: 27-37.
42. Orth JD, McNiven MA,. Dynamin at the actin-membrane interface. Curr Opin Cell Biol 2003; 15: 31-9.
43. Tõtth A, Sebestyén A, Barna G, et al,. TGF beta 1 induces caspase-dependent but death-receptor independent apoptosis in lymphoid cells. Anticancer Res 2001; 21: 1207-12.
44. Gorelik L, Flavell RA,. Transforming growth factor beta in T-cell biology. Nat Rev Immunol 2002; 2: 46-53.
45. Capocasale RJ, Lamb RJ, Vonderheid EC, et al,. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sézary patients. Proc Natl Acad Sci USA 1995; 92: 5501-5.
46. Knaus PI, Lindemann D, DeCoteau JF, et al,. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996; 16: 3480-9.
47. Lens SM, Baars PA, Hooibrink B, et al,. Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells. Immunology 1997; 90: 38-45.
48. Tesselaar K, Xiao Y, Arens R, et al,. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003; 170: 33-40.
49. Josien R, Li HL, Ingulli E, et al,. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000; 191: 495-502.
50. Storz M, Zepter K, Kamarashev J, et al,. Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides). Cancer Res 2001; 61: 452-4.
51. Kupper TS, Fuhlbrigge RC,. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-22.
52. Lowe DB, Storkus WJ,. Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy 2011; 3: 1265-74.
53. van der Fits L, van Kester MS, Qin Y, et al,. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome. J Invest Dermatol 2011; 131: 762-8.
54. Narducci MG, Arcelli D, Picchio MC, et al,. MicroRNA profiling reveals that miR-21, miR-486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome. Cell Death Dis 2011; 2: e151.
55. Ballabio E, Mitchell T, van Kester MS, et al,. MicroRNA expression in Sézary syndrome: identification, function, and diagnostic potential. Blood 2010; 116: 1105-13.
56. Manfe V, Biskup E, Rosbjerg A, et al,. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS ONE 2012; 7: e29541.
57. van Kester MS, Ballabio E, Benner MF, et al,. miRNA expression profiling of mycosis fungoides. Mol Oncol 2011; 5: 273-80.
58. Kopp KL, Ralfkiaer U, Gjerdrum LM, et al,. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 2013; 12: 1939-47.
59. Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al,. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118: 5891-900.
60. O'Neill BL, Mirvish ED, Pomerantz RG, et al,. TOX, PLS3, and KIR3DL2 genes are differentially expressed in Sézary syndrome. J Invest Dermatol 2012; 132 (Suppl. 2): S25.
61. Su M, Dorocicz I, Dragowska WH, et al,. Aberrant expression of T-plastin in Sézary cells. Cancer Res 2003; 63: 7122-7.
62. Giganti A, Plastino J, Janji B, et al,. Actin-filament cross-linking protein T-plastin increased Arp2/3-mediated actin-based movement. J Cell Sci 2005; 118: 1255-65.
63. Loebel DA, Tsoi B, Wong N, Tam PP,. A conserved noncoding intronic transcript at the mouse Dnm3 locus. Genomics 2005; 85: 782-9.
64. Kuratomi G, Komuro A, Goto K, et al,. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-β (transforming growth factor-β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-β type I receptor. Biochem J 2005; 386: 461-70.
65. Gao C, Pang L, Ren C, Ma T,. Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient. Med Oncol 2012; 29: 1733-8.
66. Poszepczynska-Guigné E, Schiavon V, D'Incan M, et al,. CD158k/KIR3DL2 is a new phenotypic marker of Sézary cells: relevance for the diagnosis and follow-up of Sézary syndrome. J Invest Dermatol 2004; 122: 820-3.
67. Mingari MC, Moretta A, Moretta L,. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today 1998; 19: 153-7.
68. Ni X, Richmond HM, Liao XM, et al,. Induction of T-cell response against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol 2008; 128: 2631-9.
69. Vermeer MH, van Doorn R, Dijkman R, et al,. Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res 2009; 68: 2689-98.
70. Maestro R, Dei Tos AP, Hamamori Y, et al,. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999; 13: 2207-17.
71. Watanabe O, Imamura H, Shimizu T, et al,. Expression of Twist and Wnt in human breast cancer. Anticancer Res 2004; 24: 3851-6.
72. Jiang L, Yuan CM, Hubacheck J, et al,. Variable CD52 expression in mature T cell and NK cell malignancies: implication for alemtuzumab therapy. Br J Haematol 2009; 145: 173-9.
73. Kitamura K, Maiti A, Ng DH, et al,. Characterization of the interaction between DC45 and CD45-AP. J Biol Chem 1995; 270: 21151-7.
74. Motoya S, Kitamura K, Matsuda A, et al,. Interaction between DC45-AP and protein-tyrosine kinases involved in T cell receptor signaling. J Biol Chem 1999; 274: 1407-14.
75. Summy JM, Gallick GE,. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-58.
76. Voice J, Donnelly S, Dorsam G, et al,. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 2004; 172: 7289-96.
77. Tesselaar K, Arens R, van Schijndel GM, et al,. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 2003; 4: 49-54.
78. Chen A, Xu H, Choi Y, et al,. TRANCE counteracts FasL-mediated apoptosis of murine bone marrow-derived dendritic cells. Cell Immunol 2004; 231: 40-8.
79. Aliahmad P, Kaye J,. Development of all CD4 T lineages requires nuclear factor TOX. J Exp Med 2008; 205: 245-56.
80. Kim S, Takahashi H, Lin WW, et al,. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
81. Liu P, Keller JR, Ortiz M, et al,. Bcl11a is essential for normal lymphoid development. Nat Immunol 2003; 4: 525-32.
82. Alvarez JD, Yasui DH, Niida H, et al,. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev 2000; 14: 521-35.
83. Jones D, Dang NH, Duvic M, et al,. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001; 115: 885-92.
84. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al,. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. Clin Exp Dermatol 2005; 30: 702-6.
85. Osella-Abate S, Zaccagna A, Savoia P, et al,. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy. J Am Acad Dermatol 2001; 44: 40-7.
86. Cory S, Adams JM,. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-56.
87. van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH,. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 1998; 77: 789-96.
88. Sommer VH, Clemmensen OJ, Nielsen O, et al,. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18: 1288-95.
89. Eriksen KW, Kaltoft K, Mikkelsen G, et al,. Constitutive STAT3-activation in Sézary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sézary cells. Leukemia 2001; 15: 787-93.
90. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, et al,. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131: 1331-8.